4UMX

IDH1 R132H in complex with cpd 1

Summary for 4UMX

• Entry DOI: 10.2210/pdb4umx/pdb
• Related: 4UMY
• Descriptor: ISOCITRATE DEHYDROGENASE [NADP] CYTOPLASMIC, 2,6-bis(1H-imidazol-1-ylmethyl)-4-(2,4,4-trimethylpentan-2-yl)phenol, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... (5 entities in total)
• Functional Keywords: oxidoreductase, isocitrate dehydrogenase inhibitor
• Biological source: HOMO SAPIENS (HUMAN)
• Cellular location: Cytoplasm : O75874
• Total number of polymer chains: 2
• Total formula weight: 98216.77

Authors

Mathieu, M.,Marquette, J.P. (deposition date: 2014-05-22, release date: 2014-11-19, Last modification date: 2024-01-10)

Primary citation

Deng, G.,Shen, J.,Yin, M.,Mcmanus, J.,Mathieu, M.,Gee, P.,He, T.,Shi, C.,Bedel, O.,Mclean, L.R.,Le-Strat, F.,Zhang, Y.,Marquette, J.,Gao, Q.,Zhang, B.,Rak, A.,Hoffmann, D.,Rooney, E.,Vassort, A.,Englaro, W.,Li, Y.,Patel, V.,Adrian, F.,Gross, S.,Wiederschain, D.,Cheng, H.,Licht, S.
Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (Idh1) Via Disruption of a Metal Binding Network by an Allosteric Small Molecule.
J.Biol.Chem., 290:762-, 2015

PubMed Abstract: Cancer-associated point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) confer a neomorphic enzymatic activity: the reduction of α-ketoglutarate to d-2-hydroxyglutaric acid, which is proposed to act as an oncogenic metabolite by inducing hypermethylation of histones and DNA. Although selective inhibitors of mutant IDH1 and IDH2 have been identified and are currently under investigation as potential cancer therapeutics, the mechanistic basis for their selectivity is not yet well understood. A high throughput screen for selective inhibitors of IDH1 bearing the oncogenic mutation R132H identified compound 1, a bis-imidazole phenol that inhibits d-2-hydroxyglutaric acid production in cells. We investigated the mode of inhibition of compound 1 and a previously published IDH1 mutant inhibitor with a different chemical scaffold. Steady-state kinetics and biophysical studies show that both of these compounds selectively inhibit mutant IDH1 by binding to an allosteric site and that inhibition is competitive with respect to Mg(2+). A crystal structure of compound 1 complexed with R132H IDH1 indicates that the inhibitor binds at the dimer interface and makes direct contact with a residue involved in binding of the catalytically essential divalent cation. These results show that targeting a divalent cation binding residue can enable selective inhibition of mutant IDH1 and suggest that differences in magnesium binding between wild-type and mutant enzymes may contribute to the inhibitors' selectivity for the mutant enzyme.

PubMed: 25391653
DOI: 10.1074/JBC.M114.608497

Experimental method

X-RAY DIFFRACTION (1.88 Å)